Features Partner Sites Information LinkXpress
Sign In

Immunoassay Control Monitors 54 Analytes Including Vitamin D

By Labmedica International staff writers
Posted on 03 Jan 2012
Print article
An immunoassay premium plus control is designed to monitor the accuracy and precision of up to 54 analytes including 25-OH Vitamin D and 1-25(OH)2 Vitamin D.

Specific target values are also provided for a wide range of fertility hormones, thyroid hormones, steroid hormones, kidney function tests, therapeutic drugs, and tumor markers. The inclusion of routinely run tumor markers and parameters such as intact parathyroid hormone (PTH) allows quality control practices to be simplified by dramatically reducing the number of controls used in the laboratory with the added benefit of cost and time savings.

The Acusera immunoassay premium plus control is being offered by Randox (Crumlin, United Kingdom). It has a shelf life of up to four years and is suitable for long-term quality control (QC) monitoring. It can significantly reduce the costs and problems associated with changing lot numbers.

In addition to low Vitamin B12 levels, the Randox Immunoassay Premium and Premium Plus controls contain ultra low levels of ferritin and thyroid stimulating hormone (TSH) as well as other vitamins. The control also contains many of the routinely run tumor markers including alpha-fetoprotein (AFP), CA15-3, CA19-9, CA-125, CEA, prostate specific antigen (PSA), and Free-PSA.

Vitamin D can also be found in the Randox RIQAS Immunoassay EQA program. RIQAS (Randox International Quality Assessment Scheme) is a large global EQA scheme with more than 20,000 participants in over 100 countries worldwide.

Related Links:


Print article



view channel
Image: Sysmex XE-5000 automated hematology analyzer (Photo courtesy of Sysmex Corporation).

Hematology Analyzers Contribute to Differentiating Febrile Illnesses

Distinguishing Dengue virus infection from other febrile thrombocytopenic illnesses such as leptospirosis or enteric fever is important but difficult, due to the unavailability of reliable diagnostic tests.... Read more

Industry News

view channel

Growth Continues in Infectious Disease Diagnostics

Global testing for infectious diseases has reached USD 16.8 Billion and the segment continues to expand from demand, growing infrastructure in emerging nations, and intense competition, according to a new healthcare market study. The findings were presented in the latest Kalorama Information (New York, NY, USA) report... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.